EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Prospective Histopathologic Comparison Between [ 18 F]PSMA-1007 PET/CT and [ 18 F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study

Robert J Hoekstra, Lisa Peeters, Alexander Beulens, Mark J Roef, Christel Brouwer, Joost Nederend, Heidi V N Küsters-Vandevelde, Harrie P Beerlage, Diederik J H Baas, Diederik M Somford, Michiel Sedelaar, Jean-Paul A van Basten und 1 weitere

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.270650 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Robert J Hoekstra und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Catharina Hospital, Eindhoven, The Netherlands; robert.hoekstra@catharinaziekenhuis.nl. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Cyclobutanes, Carboxylic Acids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Both [18F]PSMA-1007 PET/CT and [18F]fluciclovine PET/CT scans are commonly used for prostate cancer (PCa) staging. To the best of our knowledge, no head-to-head comparison of these 2 scans for detection of intraprostatic clinically significant PCa (csPCa) has been published.

Methods

A multicenter prospective histopathologic validation study was conducted from October 2020 to February 2023. Patients with newly diagnosed biopsy-proven intermediate- or high-risk PCa scheduled for robot-assisted radical prostatectomy (RARP) were consecutively included. Before RARP, patients underwent both [18F]PSMA-1007 PET/CT as well as [18F]fluciclovine PET/CT. The diagnostic accuracy of [18F]PSMA-1007 PET/CT and [18F]fluciclovine PET/CT for intraprostatic PCa detection and localization was established by histopathologic examination of the prostate specimen as reference. Sensitivity, specificity, positive predictive value, and negative predictive value were compared. Results were based on per-lesion analysis and per-segment analysis. The focus was set on csPCa, defined as the International Society of Urological Pathology grade group 2 or higher.

Results

In total, 77 patients were included of whom 57 underwent both PET/CT scans before RARP. Histopathology of the prostate specimen found a total of 88 lesions, of which 68 (77.3%) were qualified as csPCa. Using [18F]PSMA-1007 PET/CT, lesion-based sensitivity for csPCa was 86.8% (95% CI, 75.9%-93.4%), and with [18F]fluciclovine PET/CT, it was 73.5% (95% CI, 61.2%-83.2%). Sensitivity for segment-based csPCa localization was 46.6% (95% CI, 42.4%-50.8%) for [18F]PSMA-1007 PET/CT and 37.3% (95% CI, 33.3%-41.5%) for [18F]fluciclovine PET/CT. Whereas [18F]PSMA-1007 PET/CT has a significantly higher accuracy in the detection and localization of csPCa, [18F]fluciclovine PET/CT visualized all 5 non-[18F]PSMA-1007-avid index tumors.

Conclusion

Compared with [18F]fluciclovine PET/CT, [18F]PSMA-1007 PET/CT demonstrated higher sensitivity for csPCa detection. However, in non-[18F]PSMA-1007-avid tumors, the [18F]fluciclovine PET/CT can visualize csPCa and has therefore a potential role in the diagnostic work-up and the clinical decision-making process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyCyclobutanesCarboxylic AcidsNiacinamideHumansMaleProspective StudiesMiddle AgedAgedRadioactive TracersFluorine RadioisotopesOligopeptides

Stichwörter der Autor:innen

PSMAdetectionfluciclovinelocalizationprostate cancer

Substanzen

fluciclovine F-18CyclobutanesCarboxylic AcidsNiacinamidePSMA-1007Radioactive TracersFluorine RadioisotopesOligopeptides

Autor:innen und Institutionen

  • Department of Urology, Catharina Hospital, Eindhoven, The Netherlands; robert.hoekstra@catharinaziekenhuis.nl.
  • Prosper Prostate Cancer Clinics, Nijmegen, The Netherlands.
  • Department of Urology, Catharina Hospital, Eindhoven, The Netherlands.
  • Department of Nuclear Medicine, Catharina Hospital, Eindhoven, The Netherlands.
  • Department of Radiology, Catharina Hospital, Eindhoven, The Netherlands.
  • Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.

Zitieren

APA

Hoekstra, R. J., Peeters, L., Beulens, A., Roef, M. J., Brouwer, C., Nederend, J., Küsters-Vandevelde, H. V. N., Beerlage, H. P., Baas, D. J. H., Somford, D. M., Sedelaar, M., van Basten, J. A., & Vrijhof, H. J. E. J. (2026). Prospective Histopathologic Comparison Between [ 18 F]PSMA-1007 PET/CT and [ 18 F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270650

Vancouver

Hoekstra RJ, Peeters L, Beulens A, Roef MJ, Brouwer C, Nederend J, et al. Prospective Histopathologic Comparison Between [ 18 F]PSMA-1007 PET/CT and [ 18 F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.270650

BibTeX
@article{Hoekstra2026,
  author = {Hoekstra, Robert J and Peeters, Lisa and Beulens, Alexander and Roef, Mark J and Brouwer, Christel and Nederend, Joost and Küsters-Vandevelde, Heidi V N and Beerlage, Harrie P and Baas, Diederik J H and Somford, Diederik M and Sedelaar, Michiel and van Basten, Jean-Paul A and Vrijhof, Hendricus J E J},
  title = {Prospective Histopathologic Comparison Between [ 18 F]PSMA-1007 PET/CT and [ 18 F]Fluciclovine PET/CT of Intraprostatic Tumor Detection: The TRACER Study},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.270650}
}
Kostenlos starten →